Skip to main content
Canna~Fangled Abstracts

Biogenically synthesized gold nanocarrier ameliorated antiproliferative and apoptotic efficacy of doxorubicin against lung cancer

By October 29, 2024November 14th, 2024No Comments

Frontiers in Pharmacology logo

Link to Frontiers in Pharmacology

. 2024 Oct 29;15:1438237. doi: 10.3389/fphar.2024.1438237

 1,†,  2,†,  1,*,  3,4,  5,  2,*
PMCID: PMC11555439  PMID: 39534088

Abstract

Introduction

Conventional chemotherapy treatment is commonly linked to significant side effects due to high therapeutic doses. In this regard, nanoformulations with chemotherapeutic medications hold promise in enhancing drug effectiveness through the reduction of therapeutic dosages, thereby mitigating the potential for adverse side effects. Because of numerous applications in the biomedical arena, there has been a rising interest in developing an environmentally acceptable, long-lasting, and affordable technique for the production of gold nanoparticles. In this particular context, the incorporation of plant extracts in the production of metallic nanoparticles has garnered the interest of numerous scholars. Here, we report the synthesis of gold particles by the green method using Cannabis sativa L. leaf extract and their conjugation with doxorubicin.

Methods

The gold nanoparticles were synthesized by using Cannabis sativa extract and were characterized with various biophysical techniques. Subsequently, gold nanoparticles were conjugated with doxorubicin and their efficacy was tested on A549 cells.

Results and Discussion

The biogenic synthesis of gold nanoparticles was ascertained through an absorption peak at a wavelength of 524 nm, and it was shifted to 527 nm when conjugated with doxorubicin. Nanoparticles were found to be stable exhibiting a zeta potential value of −20.1 mV, and it changed to −12.7 mV when loaded with doxorubicin. The hydrodynamic diameter of nanoparticles was determined to be 45.64 nm and it was increased to 58.95 nm when conjugated with the drug. The average size of nanoparticles analyzed by TEM was found to be approximately 17.2 nm, while it was 23.5 nm in the case of drug-nanoconjugate. Moreover, there was a significant amelioration in the antiproliferative potential of doxorubicin against lung cancer A549 cells when delivered with gold nanocarrier, which was evident by the lower IC50 and IC75 values of drug-nanoconjugates in comparison to drug alone. Furthermore, the inhibitory effect of drug-nanoconjugates and drug alone was characterized by alteration in the cell morphology, nuclear condensation, increased production of reactive oxygen species, abrogation of mitochondrial membrane potential, and enhanced caspase activities in A549 cells. In sum, our results suggested enhanced efficacy of doxorubicin-gold nanoconjugates, indicating effective delivery of doxorubicin inside the cell by gold nanoparticles.

Keywords: lung cancer, nanoformulation, gold nanoparticles, Cannabis sativa L., doxorubicin, reactive oxygen species, mitochondrial membrane potential

Introduction

Lung cancer is the second most frequently diagnosed cancer and is accountable for the highest number of cancer-related mortalities, with 22,00,000 new cancer cases and 18,00,000 fatalities in 2020 (; ). In Saudia Arabia, lung carcinoma is among the foremost contributors to cancer-related mortality (). The incidence of lung cancer in Saudia Arabia has increased by a factor of 3.5 over the past 20 years (). Although in the advanced stage, first-line chemotherapy treatment involves platinum drugs as well as anthracyclines, taxanes, etc., with doxorubicin, being among the most effective. Nevertheless, low efficacy and substantial drug resistance along with severe side effects have been attributed to the use of these drugs Therefore, the development of new methods and approaches are prerequisite for the effective therapeutic management of lung cancer.

Novel nanoformulations of chemotherapeutic drugs could enhance their pharmacokinetic characteristics and thus, mitigate toxicity. Due to the significant side effects associated with traditional chemotherapeutic treatments such as doxorubicin, it is possible to decrease their dosage by combining them with a carrier or delivery agent. This approach aims to minimize the adverse effects of the drugs. Conjugating medications with a carrier facilitates targeted drug delivery to tumor cells, either nearby or directly within the cancer cells. Therefore, a reduced dosage of medication will yield greater efficacy compared to a higher therapeutic dosage. In this regard, gold nanoparticles (AuNPs) have been rigorously explored in the last 10 years due to their strong potential in the area of drug delivery, and chemotherapy (). AuNPs have drawn the most attention among nano-sized metal NPs due to their distinctive characteristics such as inertness, biocompatibility, and low toxicity (). Adequately functionalized gold nanoparticles have the potential to act as a reservoir for drugs, in addition to offering extended circulation duration and minimal cytotoxicity (). The easy surface functionalization of AuNPs with different types of molecules makes them attractive candidates for delivering various payloads (). In this context, the utilization of green chemistry for the production of metal nanoparticles offers several advantages over traditional chemical techniques. Therefore, over the past decade, a significant endeavor has been undertaken to advance the field of green chemistry for the production of gold nanoparticles. Based on anecdotal and pre-clinical evidence, hemp or industrial hemp (Cannabaceae; Cannabis sativa L.) has been reported to possess numerous medicinal properties (). An array of metabolites such as terpenoids, flavonoids, and cannabinoids are present in the extracts of Cannabis. Delta-9-tetrahydrocannabinol (THC), a major cannabinoid of Cannabis, has been shown to exhibit many pharmacological attributes including analgesic, antioxidant, anti-inflammatory, antimicrobial, and anticancer properties (; ). Thus, we hypothesized that C. sativa L. extract could be a good choice for the synthesis and surface functionalization of AuNPs. Cannabis sativa L. extract has been used previously in a few studies to synthesize gold nanoparticles (; ). Moreover, doxorubicin has also been encapsulated or attached with certain linkers with gold nanoparticles in some recent studies (; ; ; ; ). However, no report to date could show the conjugation of doxorubicin with gold nanoparticles, synthesized using C. sativa L. leaf extract. That’s why, the objective of the present investigation was to assess the potential of biogenically synthesized gold nanoparticles, using C. sativa L. extract, as a drug-carrying and delivery agent for the efficacious management of lung cancer.

Materials and methods

Materials

Doxorubicin, Tetrachloroauric (III) acid (HAuCl4.3H2O 99.9%), dyes like MTT, H2DCFDA, DAPI, and caspase colorimetric assay kits were purchased from Sigma. DMEM, FBS, Antibiotic-antimycotic solution, Pierce LDH Cytotoxicity Assay Kit, Mito Tracker Red CMXRos, and other cell culture reagents were procured from ThermoScientific, United States.

Methods

Preparation of aqueous leaf extract of Cannabis sativa L.

Cannabis sativa L. plants were a kind gift from Dr. Maqbool Ahmad Khan, Deputy Director, Central Council for Research in Unani Medicine, Basha, Kursi Road, Lucknow, 226026, UP, India. Initially, C. sativa L. fresh leaves (10 g) were taken and subjected to two sequential washes with normal water followed by three subsequent washes with autoclaved Milli-Q water to ensure complete cleanliness. Further, the leaves were subjected to crushing to fine powder utilizing a mortar and pestle, followed by transfer to a 200 mL Erlenmeyer flask that was filled with 100 mL sterile Milli-Q water. The mixture was boiled for 5–10 min (; ). Finally, the mixture was cooled and supernatant was collected after centrifugation at 2000 rpm at 4°C for 10 min. The supernatant was used for the synthesis of the gold nanoparticles. The excess supernatant was stored at −20°C.

Stock of the gold salt solution

A solution of 1 mM HAuCl4 was prepared in autoclaved sterile Milli-Q water for the synthesis of the gold nanoparticles.

Synthesis of gold nanoparticles using the Cannabis sativa L. (CNB) leaf extract

In a typical 50 mL reaction, the green synthesis of the gold nanoparticles was undertaken by adding 5 mL of the CNB leaf extract to 45 mL of 1 mM aqueous HAuCl4 and subjected to incubation for 24–48 h at 37°C (; ). Reduction of Au3+ to Au0 was constantly monitored by recording the UV-Vis absorption spectrum as a function of time. Subsequently, biosynthesized gold nanoparticles (CNB-AuNPs) were purified by centrifugation at 14,000 r.p.m. at 4°C for 45 min. The intensely red loose pellet (CNB-AuNPs) was utilized for further characterization, as well as the in vitro experiments.

Characterization of gold nanoparticles (CNB-AuNPs)

The absorption of CNB-AuNPs was monitored by a UV-VIS spectrophotometer (Eppendorf Biospectrometer® Kinetic, Eppendorf, United States). The size, shape, and morphology of the particles were determined by TEM (ThermoScientific™ Talos L120C, ThermoScientific, United States). Additionally, the hydrodynamic size and surface charge were measured using DLS (Zetasizer Nano-ZS, Model ZEN3600, Malvern Instrument Ltd., UK). To understand the role of possible functional groups, present in the plant extract, FTIR spectroscopy (Perkin Elmer Spectrum RX1, Perkin Elmer Inc., United States) was used.

Conjugation of doxorubicin (Dox) with CNB-AuNPs

Biosynthesized gold nanoparticles (CNB-AuNPs) were conjugated with doxorubicin by using 1-ethyl-3-(3-dimethylamino-propyl)-carbodiimide (EDC) as the activator (). The 5 mL of reaction contained 5 mM EDC, 50 mM HEPES buffer, 250 µg CNB-AuNPs, and 250 µg doxorubicin. The mixture was incubated for 5 h at 37°C for the coupling reaction (; ). The drug-nanoconjugates (CNB-AuNPs-Dox) were purified by centrifugation at 14,000 r.p.m. at 4°C for 45 min and further used for the detailed characterization and in vitro experiments.

Quantification of Dox in CNB-AuNPs-Dox

A standard curve for Dox (1 μg/mL to 50 μg/mL) was prepared by plotting the absorbance of Dox at 481 nm versus the concentration of Dox in µg/mL. The concentration of Dox in the supernatant of CNB-AuNPs-Dox was measured by comparing its absorbance with the standard curve. From the standard curve, we calculated the % of Dox binding in CNB-AuNPs-Dox.

Cell culture

A549 cell line was purchased from the NCCS, Pune, India. The cells were cultured in DMEM medium, which was enriched with 10% FBS and 1% antibiotic-antimycotic solution. The cells were grown at 37°C in a humidified incubator with 5% CO2.

Cytotoxicity evaluation

To test the efficacy of CNB-AuNPs-Dox, A549 cells (1 × 104/well) were grown in a 96-well plate and subjected to 24 h of incubation at 37°C. The cells were subjected to treatment with varying doses of CNB-AuNPs-Dox followed by an incubation period of 24 h (). Following incubation, the medium was removed from each well and 10 µL of MTT (5 mg/mL) was introduced to the respective wells. The plate was further kept at 37°C for 2 h. The crystals of formazan, that were produced, were solubilized in 100 µL of dimethyl sulfoxide. The absorbance of each well was taken at 570 nm with a reference filter of 630 nm using a microplate reader. The result was expressed as percent cell viability relative to control.

Lactate dehydrogenase (LDH) release assay

LDH release assay was also performed to assess CNB-AuNPs-Dox-mediated cytotoxicity in A549 cells. Briefly, cells (5 × 103 per well) were placed in a 96-well plate, followed by co-culturing with CNB-AuNPs-Dox, for 24 h. Subsequently, LDH activity was measured in all treatment groups as per the manufacturer’s instruction. Later, % cytotoxicity among all treatment groups was calculated by the given formula:

% ⁢⁢⁢⁢⁢⁢⁢⁢⁢⁢⁢=(⁢⁢⁢ ⁢⁢⁢⁢⁢⁢ ⁢⁢ ⁢⁢⁢⁢⁢⁢⁢)−(⁢⁢⁢⁢⁢⁢⁢⁢⁢⁢ ⁢⁢ ⁢⁢⁢⁢⁢⁢⁢)⁢⁢⁢⁢⁢⁢ ⁢⁢ ⁢⁢⁢⁢⁢⁢⁢−⁢⁢⁢⁢⁢⁢⁢⁢⁢⁢ ⁢⁢ ⁢⁢⁢⁢⁢⁢⁢×100

Assessing morphological changes in A549 cells

Morphological alterations in CNB-AuNPs-Dox-treated lung cancer cells were analyzed by phase contrast microscopy. Briefly, A549 cells (5 × 103/well) were grown in a 96-well plate and subjected to 24 h incubation. Thereafter, cells were treated with IC50 and IC75 of CNB-AuNPs-Dox and incubated for 24 h at 37°C. Subsequently, the alterations in cell morphology of treated and control cells were examined using FLoid imaging station (ThermoScientific, United States).

Examination of nuclear alterations

The apoptotic effect of CNB-AuNPs-Dox was investigated against A549 cells using DAPI staining. The cells were grown and treated with nanoconjugates in the same manner as mentioned above. Subsequently, the cells were rinsed with PBS and fixed for 10 min in 4% paraformaldehyde. Later, the cells were permeabilized (3% paraformaldehyde and 0.5% Triton X-100) and stained with DAPI. Later, cells were observed under a blue filter (Excitation: Emission:390/40 nm: 446/33 nm) using FLoid Imaging station.

Mitochondrial membrane potential (∆Ψm) assessment

The ∆Ψm was measured in A549 cells, treated with CNB-AuNPs-Dox, using Mito Tracker Red CMX Ros labeling. In a 24-well plate, cells (1 × 105 per well) were seeded and allowed for 24 h incubation. Cells were then co-cultured for 24 h with CNB-AuNPs-Dox. Further, cells were washed and stained for 30 min in the dark with Mito Tracker Red (300 nM), and images were captured using FLoid Imaging station.

Intracellular reactive oxygen species (ROS) generation

The fluorogenic dye H2DCFDA was used to detect A549 cells treated with CNB-AuNPs-Dox. A549 cells (1 × 104/well) were seeded and subjected to overnight incubation at 37°C. Subsequently, cells were treated for another 24 h with varying doses of CNB-AuNPs-Dox, followed by staining with H2DCFDA (25 µM) for 30 min at 37°C. Later, in each well, the media was replaced with 200 µL of PBS for washing. Finally, images were captured using FLoid imaging station.

Additionally, to determine the amount of ROS, cells (1 × 104/well) were grown a in 96-well black bottom culture plate and subjected to overnight incubation at 37°C. A549 cells were then exposed to CNB-AuNPs-Dox for another 12 h, followed by incubation with H2DCFDA (25 µM) for 30 min at 37°C. Fluorescence intensity was recorded via a multi-mode microplate reader.

Determination of caspase activity

Briefly, A549 cells were treated with different concentrations of CNB-AuNPs-Dox and incubated for another 24 h. Later, caspase activities were measured according to the manufacturer’s instructions.

Statistical analysis

Data shown in this study are mean ± standard deviation (S.D.) of three individual experiments performed in triplicate. Statistical analysis was done using one-way ANOVA followed by Dunnett post-hoc test and two-way ANOVA with Tukey multiple comparison test (*p < 0.05, **p < 0.01, and ***p < 0.001 denote level of significance between means of treatment groups).

Results

Cannabis sativa L. leaf extract mediated synthesis of gold nanoparticles (AuNPs)

At the outset, a sequence of experiments was executed to optimize the reaction conditions to biosynthesize gold nanoparticles (AuNPs). Subsequently, the results indicated that CNB leaf extract produced stable gold nanoparticles (CNB-AuNPs) which were used for the detailed characterization as well as the in vitro experiments. Secondary metabolites and reducing enzymes of the aqueous CNB leaf extract are thought to trigger the synthesis of gold nanoparticles (CNB-AuNPs).

Characterization of CNB-AuNPs and conjugation of Dox with AuNPs

Upon mixing the leaf extract with the aqueous solution of chloroauric acid (HAuCl4), the change in solution color from light yellow to ruby red indicated the synthesis of gold nanoparticles (CNB-AuNPs). An absorbance peak at 524 nm was observed corresponding to the characteristic surface plasmon resonance of gold (Figure 1A). The result has substantiated the synthesis of AuNPs, given that the existence of a peak at approximately 524 nm serves as a distinctive indication to recognize gold nanoparticles (). The dynamic light extracting (DLS) method was used to determine the average particle size and distribution of CNB-AuNPs, which had an average particle size of 45.64 nm as shown in Figure 1C. Furthermore, the zeta potential of the synthesized CNB-AuNPs was found to be −20.1 mV at room temperature, suggesting the high stability of nanoparticles (Figure 1E). The TEM micrograph confirmed the average size of CNB-AuNPs to be 17.2 nm and also, they seemed to be mono-dispersed (Figure 1G). The FTIR spectra showed that gold nanoparticles (Figure 2B) exhibited the chemical groups present in the leaf extract (Figure 2A). The FTIR spectrum of CNB-AuNPs exhibited medium absorption bands at 3,402.02 cm−1 due to O-H stretching vibrations of alcohols (). The peak around 2,919.12 cm−1 corresponds to C-H stretching. The band at 1,620.59 cm−1 could be linked with a C=C conjugated bond (). The peak near 1,383.67 cm−1 and 1,086.44 cm−1 corresponds to vibration of the O-H (alcohol) and C-N (amines) stretch, respectively.

FIGURE 1.

FIGURE 1

Open in a new tab
Characterization of CNB-AuNPs (A, C, E, G) and CNB-AuNPs-Dox (B, D, F, H) by UV-Visible spectra, Hydrodynamic diameter, Zeta potential, and Transmission Electron Microscopy, respectively.

FIGURE 2.

FIGURE 2

Open in a new tab
FTIR spectra of (A) Cannabis sativa leaf extract (B) CNB-AuNPs (C) Dox (D) CNB-AuNPs-Dox.

Conjugation of Dox with AuNPs was characterized by a shift in the spectra towards a higher wavelength (from 524 nm to 527 nm) as observed by UV-Vis spectroscopy (Figure 1B). Further, the hydrodynamic diameter of particles was found to be increased to 58.95 nm after conjugation (Figure 1D). The zeta potential of CNB-AuNPs-Dox was found to be −12.7 mV (Figure 1F). TEM depicts the image of CNB-AuNPs-Dox with an increase in average size (23.5 nm) which further confirmed conjugation. After conjugation, it was observed that the mean size had increased marginally in comparison to that of AuNPs, owing to the attachment of Dox onto the surface of the nanoparticles. CNB-AuNPs-Dox nanoconjugates were observed to possess a spherical shape and exhibit mono-dispersed characteristics, as confirmed by the TEM micrograph (Figure 1H). The FTIR spectra confirmed the conjugation of Dox with gold nanoparticles (Figures 2C, D). In the FTIR spectrum of Dox, the bend peaks of N-H bonds were observed at 1,634.77 cm−1 and N-H stretching at 3,434.25 cm−1. The bend peaks of O-H bonds (phenol) were also observed at 1,383.44 cm−1. Two peaks of C-N (amine) stretching at 1,155.51 cm−1 and 1,083.63 cm−1 were also observed. The spectrum of CNB-AuNPs-Dox was compared with Dox and it was found that the medium absorption band at 3,434.26 cm−1 was due to N-H stretching vibrations of amide bond present on AuNPs confirming conjugation of Dox. Further, the peak at 1,635.32 cm−1 probably represents the N-H group bending of the amine group of Dox. The bend peaks of O-H bonds (phenol) were also shifted and observed at 1,383.49 cm−1. A peak at 1,084.25 cm−1 corresponds to a stretch of C-N of peptide bond which also confirmed the conjugation of Dox.

Drug loading efficiency

After conjugation, the quantitative estimation of the loading of Dox on CNB-AuNPs was carried out by taking the absorbance of both the total drug added and unbound drug following conjugation via UV-Vis spectroscopy at a wavelength of 481 nm. The amount of Dox conjugated to CNB-AuNPs was found to be 46.24% ± 3.98%, thus revealing substantial binding of the drug with nanoparticles.

In vitro cytotoxicity of gold-drug nanoconjugates

To assess the responsiveness of lung carcinoma cells to drug-loaded nanoparticles and establish their optimal dosage, A549 cells were subjected to varying concentrations of drug-nanoconjugates for a duration of 24 h, following which the percentage of cell viability was calculated by performing MTT assay. As can be seen in Figure 3, CNB-AuNPs-Dox (0.025–0.80 μg/mL) substantially inhibited the viability of A549 cells after 24 h of treatment. At the dose of 0.025, 0.05, 0.1, 0.2, 0.4, 0.6, and 0.80 μg/mL, the cell viability was found to be 97.40% ± 1.47%, 84.94% ± 1.39%, 72.14% ± 1.66%, 58.69% ± 1.75%, 42.55% ± 2.08%, 25.41% ± 1.81%, and 7.36% ± 1.01%, respectively (Figure 3). Similarly, Dox also reduced the survival of A549 cells at the dose of 0.2, 0.4, 0.6, 0.8 1.0, 1.2, and 1.4 μg/mL; and viability was found to be 94.26% ± 2.29%, 83.80% ± 2.38%, 74.12% ± 3.60%, 65.56% ± 4.22%, 55.69% ± 3.27%, 30.44% ± 7.69%, and 12.08% ± 2.75%, respectively (Figure 3). Furthermore, CNB-AuNPs alone, at the dose of 0.2, 0.4, 0.6, 0.80. and 1.0 μg/mL, exerted insignificant effect on A549 cells (Figure 3). On analyzing the data, we observed that gold-doxorubicin nanoconjugates induce a strong cytotoxic effect in comparison to doxorubicin at similar doses of treatment, while CNB-AuNPs alone exhibited an insignificant effect on A549 cells at equivalent concentrations. However, CNB-AuNPs were found to be cytotoxic against A549 cells in the range of 5–50 μg/mL (Figure 3).

FIGURE 3.

FIGURE 3

Open in a new tab
Percent cell viability of A549 cells of CNB-AuNPs-Dox, Dox, and CNB-AuNPs for 24 h assessed by MTT assay along with their respective IC50 and IC75 values. The results presented are the mean ± SD of three independent experiments performed in triplicate. Significance among different dosage groups was determined using one-way ANOVA followed by the Dunnett post-hoc test (where *p < 0.05, **p < 0.01, and ***p < 0.001 represent significant differences compared with vehicle control).

The IC50 and IC75 of CNB-AuNPs-Dox were found to be 0.24 μg/mL and 0.52 μg/mL, respectively. Similarly, IC50 and IC75 of Dox were 0.92 μg/mL and 1.27 μg/mL, respectively. However, IC50 and IC75 of CNB-AuNPs alone were 14.96 μg/mL and 28.31 μg/mL, respectively. Here, the isoeffective doses of CNB-AuNPs-Dox were substantially reduced in comparison to Dox alone which signified that CNB-AuNPs-Dox exert a similar effect on A549 cells at a much lower dose in comparison to Dox. Thus, the result suggested the effective delivery of doxorubicin inside cells by drug-gold nanoconjugates (Figure 5).

FIGURE 5.

FIGURE 5

Open in a new tab
Comparison of the efficacy of CNB-AuNPs-Dox, Dox, and CNB-AuNPs against A549 cells in terms of cell viability and cytotoxicity. The results presented are the mean ± SD of three independent experiments performed in triplicate. Significance among different dosage groups was determined using two-way ANOVA followed by Tukey’s multiple comparison tests (where *p < 0.05, **p < 0.01, and ***p < 0.001 represent significant differences between means of different treatment groups).

LDH release assay

The results showed that treatment of CNB-AuNPs-Dox for 24 h, caused substantial cell death in A549 cells, as compared to untreated control; and percent cytotoxicity was found to be 3.76% ± 0.73%, 13.97% ± 0.83%, 28.88% ± 1.79%, 42.62% ± 1.85%, 59.12% ± 1.74%, 75.71% ± 2.09%, and 92.93% ± 0.79% at the dose of 0.025, 0.05, 0.1, 0.2, 0.4, 0.6 and 0.80 μg/mL, respectively (Figure) Similarly, Dox also caused cytotoxicity of 6.97% ± 1.24%, 17.16% ± 1.37%, 26.55% ± 2.04%, 35.51% ± 2.25%, 45.05% ± 2.14%, 72.84% ± 2.44%, and 88.11% ± 1.92% at the dose of 0.2, 0.4, 0.6, 0.80, and 1.0 μg/mL, respectively (Figure). Additionally, CNB-AuNPs alone exerted an insignificant effect on A549 cells at the dose of 0.2, 0.4, 0.6, 0.80, and 1.0 μg/mL (Figure 4). Thus, the results showed that drug-gold nanoconjugate caused more cytotoxicity in A549 cells at similar doses when compared to Dox alone, which could be due to efficient uptake of drug by cells via drug-gold nanocarrier (Figure 5).

FIGURE 4.

FIGURE 4

Open in a new tab
Percent cytotoxicity of A549 cells treated with various doses of CNB-AuNPs-Dox, Dox, and CNB-AuNPs for 24 h assessed by LDH release assay. The results presented are the mean ± SD of three independent experiments performed in triplicate. Significance among different dosage groups was determined using one-way ANOVA followed by the Dunnett post-hoc test (where *p < 0.05, **p < 0.01, and ***p < 0.001 represent significant differences compared with vehicle control).

Cytomorphological changes in A549 cells

To analyze cytomorphological changes in A549 cells, caused by drug-gold nanoconjugates, cells were co-cultured with IC50 and IC75 of CNB-AuNPs-Dox as well as Dox and CNB-AuNPs and were observed under a microscope. A549 cells in all the treated groups exhibited a change in cell morphology that was dependent on the dose administered (Figure 6). The cells in the untreated control group exhibited a well-spread, flattened morphology. Conversely, the A549 cells in all treatment groups displayed a rounded morphology with slight shrinkage. A subset of cells exhibited signs of cytotoxicity in A549 cells, as evidenced by cellular swelling, and cell membrane lysis. As the treatment dose was increased from IC50 to IC75, these changes in A549 cells were substantially increased in all the treatment groups. Here also, CNB-AuNPs-Dox instigated comparable changes in A549 cells at lesser doses in comparison to DOX, which was in line with our above results.

FIGURE 6.

FIGURE 6

Open in a new tab
Cytomorphological images of A549 cells treated with IC50 and IC75 of CNB-AuNPs-Dox, Dox, and CNB-AuNPs for 24 h were analyzed by phase contrast microscopy. The images shown are representative of three independent experiments performed in triplicate (Magnification ×20; Scale bar 100 µm).

Nuclear changes in A549 cells

DAPI staining was conducted to probe and determine if the suppression of cell proliferation in A549 cells treated with CNB-AuNPs-Dox was indeed a result of apoptosis. As shown in Figure 7, significant nuclear alterations were observed in cells among all the treatment groups (Figure 7). CNB-AuNPs-Dox, Dox, and CNB-AuNPs, at their respective IC50 and IC75, induced nuclear changes in A549 cells, whereas the cells showed normal nuclei in the control group. As the dose was increased from IC50 to IC75, the nuclear changes in A549 cells were significantly increased in all the treated groups. As observed above, CNB-AuNPs-Dox exerted corresponding nuclear alterations in A549 cells at lower doses when compared with Dox.

FIGURE 7.

FIGURE 7

Open in a new tab
Nuclear morphology of DAPI stained nuclei of A549 cells treated with IC50 and IC75 of CNB-AuNPs-Dox, Dox, and CNB-AuNPs for 24 h analyzed by fluorescence microscopy. The images shown are representative of three independent experiments (Scale bar: 100μm; Magnification: ×20).

Reduction in the mitochondrial membrane potential (ΔΨm)

The mitochondrial pathway of apoptosis is activated by the abrogation of the ΔΨm. Thus, to determine, whether apoptosis induced in CNB-AuNPs-Dox-treated lung cancer cells was due to disruption of ΔΨm, A549 cells were co-cultured with IC50 and IC75 of CNB-AuNPs-Dox as well as Dox and CNB-AuNPs for 24 h and were examined after staining with Mitotracker Red CMXRos dye. Subsequently, a substantial reduction in ΔΨm of A549 cells was observed in all the treated groups (Figure 8). The maximum fluorescence intensity of the Mitotracker dye was seen in untreated control cells followed by a gradual decline in the fluorescence among cells of all the treated groups. As the dose was increased from IC50 to IC75, ΔΨm in A549 cells was further decreased in all the treatment groups. Like previous observations, CNB-AuNPs-Dox caused an equivalent reduction in ΔΨm in A549 cells at lower doses when compared with Dox alone.

FIGURE 8.

FIGURE 8

Open in a new tab
Qualitative assessment of Mitochondrial Membrane Potential in Mitotracker Red-stained A549 cell treated with IC50 and IC75 of CNB-AuNPs-Dox, Dox, and CNB-AuNPs for 24 h analyzed by fluorescence microscopy. The images shown are representative of three independent experiments (Scale bar: 100 μm; Magnification: ×20).

Augmentation of reactive oxygen species (ROS)

The escalation of intracellular ROS generation has been widely documented as a significant impetus for the initiation of apoptosis. Therefore, to investigate, whether drug-induced apoptosis in A549 cells was due to intracellular ROS generation, H2DCFDA staining was done. The intensity of DCF fluorescence is directly proportional to the intracellular level of ROS. Among all the treatment groups, A549 cells showed a dose-dependent increase in DCF fluorescence, whereas insignificant fluorescence was observed in untreated control cells (Figure 9). As the treatment dose was increased from IC50 to IC75, ROS generation in A549 cells was further increased in all the treatment groups. As observed above, CNB-AuNPs-Dox caused comparable augmentation in ROS generation in A549 cells at lower doses when compared with Dox alone. In an additional experiment, intracellular ROS level was quantified and the result was shown as percent DCF-fluorescence relative to control in A549 cells among all treatment groups. A concentration-dependent augmentation in DCF-fluorescence was observed in A549 cells treated with CNB-AuNPs-Dox as well as Dox (Figure 10). However, CNB-AuNPs-Dox-treatment induced greater ROS production in A549 cells, at similar doses, when compared to Dox alone.

FIGURE 9.

FIGURE 9

Open in a new tab
Qualitative evaluation of ROS in H2DCFDA stained A549 cells treated with IC50 and IC75 of CNB-AuNPs-Dox, Dox, and CNB-AuNPs for 24 h analyzed by fluorescence microscopy. The images shown are representative of three independent experiments (Scale bar: 100μm; Magnification: ×20).

FIGURE 10.

FIGURE 10

Open in a new tab
Quantitative determination of ROS in H2DCFDA-stained A549 cells treated with various concentrations of CNB-AuNPs-Dox, Dox, and CNB-AuNPs for 24 h. The results presented are the mean ± SD of three independent experiments performed in triplicate. Significance among different dosage groups was determined using two-way ANOVA followed by Tukey’s multiple comparison tests (where *p < 0.05, **p < 0.01, and ***p < 0.001 represent significant differences between means of different treatment groups).

Activation of caspases

As caspase-9 and -3 play a key role in activating the intrinsic pathway, we set out to determine whether the induction of apoptosis in CNB-AuNPs-Dox-treated A549 cells was due to activation of caspases. Thus, caspase-9 and -3 activity were measured in A549 cells treated with varying concentrations of CNB-AuNPs-Dox as well as Dox and CNB-AuNPs. Our results showed a significant augmentation in caspase-3 and -9 activities in A549 cells, treated with CNB-AuNPs-Dox as well as Dox (Figure 11). However, CNB-AuNPs-Dox exerted more pronounced caspase-3 and -9 activities in A549 cells in comparison to Dox alone, at similar doses.

FIGURE 11.

FIGURE 11

Open in a new tab
Estimation of Caspase-9, and Caspase-3 activities in A549 cells treated with various concentrations of CNB-AuNPs-Dox, Dox, and CNB-AuNPs for 24 h. The results presented are the mean ± SD of three independent experiments performed in triplicate. Significance among different dosage groups was determined using two-way ANOVA followed by Tukey’s multiple comparison tests (where *p < 0.05, **p < 0.01, and ***p < 0.001 represent significant differences between means of different treatment groups).

Discussion

Around 85% of lung cancer incidences are characterized as non-small cell lung cancer (NSCLC). It is the foremost contributor to tumor-related mortality globally, underscoring the necessity for improved and efficacious therapeutic interventions (). NSCLC exhibits inherent resistance and typically lacks responsiveness to primary chemotherapy. The administration of doxorubicin as a therapeutic intervention for advanced NSCLC yields a mere 30%–50% overall response rate (). Unfortunately, the acute and cumulative toxicity related to the dose, in conjunction with significant drug resistance, presents a significant challenge to therapeutic outcomes. In this regard, the nanoparticle-based drug delivery method has been shown to be very effective in cancer therapy (; ). The biocompatibility and lack of toxicity exhibited by AuNPs render them an outstanding contender for drug delivery purposes (; ). Several researchers have employed chemotherapy as a treatment modality for lung carcinoma utilizing Dox (; ; ; ; ). Nevertheless, the utilization of this therapeutic agent in clinical settings is restricted due to its adverse side effects, with cardiotoxicity being the most remarkable. Hence, researchers are endeavoring to design novel delivery mechanisms in order to curtail its adverse reactions and intensify its therapeutic potency. To date, no study has reported the conjugation of Dox with AuNPs, synthesized by using C. sativa L. extract. Therefore, we studied the potential of AuNPs to serve as a nanocarrier for Dox.

Biogenically synthesized CNB-AuNPs were characterized using UV-Vis spectroscopy. The confirmation of CNB-AuNPs synthesis was ascertained through the observation of an absorption peak at a wavelength of 524 nm. Our findings are consistent with a previous study in which it was demonstrated that the highest peaks of AuNPs fall within the range of 520–560 nm (). CNB-AuNPs exhibit a zeta potential value of −20.1 mV, indicating that these nanoparticles possess notable stability owing to the electrostatic repulsive force (). The hydrodynamic diameter of gold nanoparticles was determined to be 45.64 nm through the utilization of the dynamic light scattering (DLS) technique. The identification of the size and morphology of AuNPs was carried out via the utilization of TEM. The observed average size of CNB-AuNPs was determined to be approximately 17.2 nm. After the conjugation reaction, the samples were analyzed by various biophysical techniques to characterize the conjugation of Dox with AuNPs. CNB-AuNPs-Dox were observed to exhibit a pronounced peak at 527 nm upon analysis via UV-Vis spectroscopy. The hydrodynamic diameter of CNB-AuNPs-Dox was determined to be 58.95 nm. This observed increase in size may be attributed to the conjugation of Dox with CNB-AuNPs. The high stability of the nanoemulsion of CNB-AuNPs-Dox is also evidenced by its negative zeta potential of −12.7 mV. The findings of the TEM analysis demonstrated that the CNB-AuNPs-Dox exhibited an average size of 23.5 nm, which was marginally larger in comparison to the CNB-AuNPs. This can be attributed to the coupling of Dox over the surface of CNB-AuNPs. Our findings are consistent with a prior report where Dox has been shown to conjugate with iron oxide nanoparticles (). Another study also reported the conjugation of Dox with zinc nanoparticles (). In an interesting study, Dox has been shown to conjugate with zinc oxide nanoparticles using glutaraldehyde ().

The results of the cytotoxicity assay showed that CNB-AuNPs-Dox as well as DOX were effective in reducing the proliferation of A549 cells; however, the effectiveness of CNB-AuNPs-Dox was found to be significantly increased at lower doses when compared to Dox. The enhanced activity of CNB-AuNPs-Dox can most plausibly be attributed to the high drug loading capacity of the gold-nanocarrier and effective drug delivery. This could potentially lead to a significant increase in the intracellular concentration of Dox, ultimately resulting in an enhanced reduction in cancer cell proliferation. Our findings are consistent with a prior investigation, in which Dox, when conjugated to AuNPs utilizing an acid-labile linker, exhibited heightened cytotoxicity against the multidrug-resistant MCF-7/ADR breast cancer cell line. This indicates that the AuNPs-bound drug is taken up more readily and subsequently released within the cell responsively, resulting in a partial reversal of multidrug resistance (). In an additional in vitro investigation, it was observed that conjugates of oxaliplatin with PEG-coated/carboxylate-capped AuNPs exhibit a greater degree of cytotoxicity as compared to free oxaliplatin in HCT15, HT29, and RKO colon cancer cell lines (). 5-fluorouracil (5-FU), conjugated with glutathione-caped AuNPs, exhibited an enhanced anticancer effect in colorectal cancer cells when compared to 5-FU alone (). The cytotoxicity of Capecitabine, cisplatin, or doxorubicin conjugated to L-aspartate-stabilized AuNPs was found to be higher towards hepatocellular carcinoma cells than that of free capecitabine, free cisplatin or doxorubicin (). In another in vitro investigation, the conjugation of etoposide to hydroxy propyl methylcellulose/polyvinyl alcohol-functionalized AuNPs exhibited enhanced cytotoxicity effects on the NCI-H69 cell line in comparison to free etoposide (). Methotrexate (MTX), when conjugated with AuNPs, exhibited increased cytotoxicity against a variety of tumor cell lines in comparison to free MTX. The accumulation of MTX in tumor cells was observed to occur at a more rapid pace and to a greater extent when conjugated with AuNPs (). These studies support the high drug loading efficiency of AuNPs which can be utilized to formulize novel drug nanoformulations. Although we have not studied how the Dox is delivered inside the cell by CNB-AuNPs, the previous studies have established that the energy-dependent endocytic pathways are important for the internalization of nanoparticles inside the cell (; ).

Furthermore, cytomorphological analysis, performed by phase contrast microscopy, showed that the shapes of A549 cells were significantly changed in all the treatment groups at respective IC50 and IC75, and were characterized by shrinking and detachment. Likewise, DAPI staining in A549 cells, at respective IC50 and IC75, showed chromatin condensation with bright blue nuclei, indicating initiation of apoptosis. Furthermore, CNB-AuNPs-Dox exerted similar alterations in A549 cells at lower doses in comparison to Dox alone. As shown previously, the loss of Δψm is an early hallmark of apoptosis (). Interestingly, A549 cells, at respective IC50 and IC75, showed a gradual decrease. CNB-AuNPs-Dox reduced the Δψm in A549 cells at lower concentrations in comparison to DOX signifying effective intracellular delivery of the drug.

The onset of elevated basal oxidative stress can be attributed to the overproduction of ROS in cancer cells. The state of oxidative stress that cancer cells experience renders them susceptible to therapeutic agents that could enhance ROS levels. Hence, pro-oxidants are increasingly being viewed as promising candidates to selectively target tumor cells (). Qualitative examination depicted augmentation in the ROS level in A549 cells in all the treatment groups at respective IC50 and IC75. CNB-AuNPs-Dox induced a comparable amount of ROS generation in A549 cells at lower concentrations as compared to Dox alone. Additionally, quantitative examination of ROS showed that CNB-AuNPs-Dox, as well as Dox, were efficient in increasing ROS generation in A549 cells; nevertheless, the effectiveness of CNB-AuNPs-Dox was more reflective at lower doses when compared to Dox alone.

Caspases are produced in an inert proenzyme state and their activation during the process of apoptosis leads to cleavage at distinct sites (; ). The caspases-8 and -9, acting as initiators, undergo self-catalytic activation, while the caspase-3, responsible for execution, is activated by the aforementioned initiator caspases. Caspase-3 is a critical mediator of programmed cell death and is accountable for the proteolytic cleavage of numerous cellular proteins (). Results of the study revealed that CNB-AuNPs-Dox as well as Dox caused significant caspase-3 and -9 activation in A549 cells; though, the effect of CNB-AuNPs-Dox was more pronounced at lower doses when compared to Dox.

Conclusion

In the present investigation, we have demonstrated the synthesis of gold nanoparticles through a green chemistry methodology that is simple, effective, cost-efficient, and environmentally sustainable. Several physicochemical methods were used to systematically characterize the nanoparticles. Later, doxorubicin-gold nanoconjugates were shown to exert substantial inhibition of lung cancer cell proliferation in comparison to free doxorubicin. In sum, our results demonstrated the efficacy of a biogenic gold nanoparticle-based drug-delivery system against lung cancer cells which could be tested in pre-clinical and clinical settings in the near future for the development of an alternative cost-effective treatment approach for cancer therapy.

Funding Statement

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research has been funded by Deputy for Research & Innovation, Ministry of Education through Initiative of Institutional Funding at University of Ha’il – Saudi Arabia through project number IFP-22 108.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. Ethical approval was not required for the studies on animals in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.

Author contributions

YA: Writing–review and editing, Funding acquisition, Conceptualization, Writing–original draft, Formal Analysis. PM: Validation, Methodology, Investigation, Writing–original draft, Formal Analysis. MS: Writing–original draft, Visualization, Resources, Formal Analysis, Data curation, Conceptualization. NA: Writing–review and editing, Supervision, Formal Analysis. TQ: Writing–original draft, Software, Project administration, Data curation. IA: Writing–review and editing, Writing–original draft, Formal Analysis, Data curation, Conceptualization.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1438237/full#supplementary-material

Image1.TIF (6.5MB, TIF)

References

  1. Ajnai G., Chiu A., Kan T., Cheng C.-C., Tsai T.-H., Chang J. (2014). Trends of gold nanoparticle-based drug delivery system in cancer therapy. J. Exp. and Clin. Med. 6 (6), 172–178. 10.1016/j.jecm.2014.10.015 [DOI] [Google Scholar]
  2. Aldalbahi A., Alterary S., Ali Abdullrahman Almoghim R., Awad M. A., Aldosari N. S., Fahad Alghannam S., et al. (2020). Greener synthesis of zinc oxide nanoparticles: characterization and multifaceted applications. Molecules 25 (18), 4198. 10.3390/molecules25184198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ali M. M., Rajab N. A., Abdulrasool A. A. (2020). Etoposide-loaded gold nanoparticles: preparation, characterization, optimization and cytotoxicity assay. Syst. Rev. Pharm. 11 (2), 372–381. [Google Scholar]
  4. Aljabali A. A. A., Akkam Y., Al Zoubi M. S., Al-Batayneh K. M., Al-Trad B., Abo Alrob O., et al. (2018). Synthesis of gold nanoparticles using leaf extract of Ziziphus zizyphus and their antimicrobial activity. Nanomaterials 8 (3), 174. 10.3390/nano8030174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Almatroudi A. (2021). A retrospective cohort study of lung cancer incidences and epidemiological analysis in Saudi arabian population from 2006-2016. Int. J. Environ. Res. Public Health 18 (22), 11827. 10.3390/ijerph182211827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Amreddy N., Muralidharan R., Babu A., Mehta M., Johnson E. V., Zhao Y. D., et al. (2015). Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int. J. Nanomedicine 10, 6773–6788. 10.2147/IJN.S93237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Anik M. I., Mahmud N., Al Masud A., Hasan M. (2022). Gold nanoparticles (GNPs) in biomedical and clinical applications: a review. Nano Sel. 3 (4), 792–828. 10.1002/nano.202100255 [DOI] [Google Scholar]
  8. Aryal S., Grailer J. J., Pilla S., Steeber D. A., Gong S. (2009). Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers. J. Mater. Chem. 19 (42), 7879–7884. 10.1039/b914071a [DOI] [Google Scholar]
  9. Bagga P., Ansari T. M., Siddiqui H. H., Syed A., Bahkali A. H., Rahman M. A., et al. (2016). Bromelain capped gold nanoparticles as the novel drug delivery carriers to aggrandize effect of the antibiotic levofloxacin. EXCLI J. 15, 772–780. 10.17179/excli2016-710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Brown S. D., Nativo P., Smith J. A., Stirling D., Edwards P. R., Venugopal B., et al. (2010). Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J. Am. Chem. Soc. 132 (13), 4678–4684. 10.1021/ja908117a [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chen Y. H., Tsai C. Y., Huang P. Y., Chang M. Y., Cheng P. C., Chou C. H., et al. (2007). Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. Mol. Pharm. 4 (5), 713–722. 10.1021/mp060132k [DOI] [PubMed] [Google Scholar]
  12. Chouhan S., Guleria S. (2020). Green synthesis of AgNPs using Cannabis sativa leaf extract: characterization, antibacterial, anti-yeast and α-amylase inhibitory activity. Mater. Sci. Energy Technol. 3, 536–544. 10.1016/j.mset.2020.05.004 [DOI] [Google Scholar]
  13. Datkhile K. D., Durgawale P. P., Chakraborty S., Jagdale N. J., More A. L., Patil S. R. (2023). Biogenic nanoparticles: synthesis, characterization, and biological potential of gold nanoparticles synthesized using Lasiosiphon eriocephalus decne plant extract. Pharm. Nanotechnol. 11 (3), 303–314. 10.2174/2211738511666230206112537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dhamecha D., Jalalpure S., Jadhav K., Jagwani S., Chavan R. (2016). Doxorubicin loaded gold nanoparticles: implication of passive targeting on anticancer efficacy. Pharmacol. Res. 113 (Pt A), 547–556. 10.1016/j.phrs.2016.09.037 [DOI] [PubMed] [Google Scholar]
  15. El-Deeb N. M., Khattab S. M., Abu-Youssef M. A., Badr A. M. A. (2022). Green synthesis of novel stable biogenic gold nanoparticles for breast cancer therapeutics via the induction of extrinsic and intrinsic pathways. Sci. Rep. 12 (1), 11518. 10.1038/s41598-022-15648-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. (1998). A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391 (6662), 43–50. 10.1038/34112 [DOI] [PubMed] [Google Scholar]
  17. Hong S., Rattan R., Majoros I. J., Mullen D. G., Peters J. L., Shi X., et al. (2009). The role of ganglioside GM1 in cellular internalization mechanisms of poly(amidoamine) dendrimers. Bioconjug Chem. 20 (8), 1503–1513. 10.1021/bc900029k [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Iram S., Zahera M., Wahid I., Baker A., Raish M., Khan A., et al. (2019). Cisplatin bioconjugated enzymatic GNPs amplify the effect of cisplatin with acquiescence. Sci. Rep. 9 (1), 13826. 10.1038/s41598-019-50215-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Josiah A. J., Pillai S. K., Cordier W., Nell M., Twilley D., Lall N., et al. (2021). Cannabidiol-mediated green synthesis, characterization, and cytotoxicity of metal nanoparticles in human keratinocyte cells. ACS Omega 6 (43), 29078–29090. 10.1021/acsomega.1c04303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Khan I., Khan F., Farooqui A., Ansari I. A. (2018). Andrographolide exhibits anticancer potential against human colon cancer cells by inducing cell cycle arrest and programmed cell death via augmentation of intracellular reactive oxygen species level. Nutr. Cancer 70 (5), 787–803. 10.1080/01635581.2018.1470649 [DOI] [PubMed] [Google Scholar]
  21. Khutale G. V., Casey A. (2017). Synthesis and characterization of a multifunctional gold-doxorubicin nanoparticle system for pH triggered intracellular anticancer drug release. Eur. J. Pharm. Biopharm. 119, 372–380. 10.1016/j.ejpb.2017.07.009 [DOI] [PubMed] [Google Scholar]
  22. Kong F. Y., Zhang J. W., Li R. F., Wang Z. X., Wang W. J., Wang W. (2017). Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications. Molecules 22 (9), 1445. 10.3390/molecules22091445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Leite F. L., Bueno C. C., Da Roz A. L., Ziemath E. C., Oliveira O. N. (2012). Theoretical models for surface forces and adhesion and their measurement using atomic force microscopy. Int. J. Mol. Sci. 13 (10), 12773–12856. 10.3390/ijms131012773 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Li D., Ilnytskyy Y., Ghasemi Gojani E., Kovalchuk O., Kovalchuk I. (2022). Analysis of anti-cancer and anti-inflammatory properties of 25 high-THC cannabis extracts. Molecules 27 (18), 6057. 10.3390/molecules27186057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Liu D., Yang F., Xiong F., Gu N. (2016). The smart drug delivery system and its clinical potential. Theranostics 6 (9), 1306–1323. 10.7150/thno.14858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lucas C. J., Galettis P., Schneider J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol. 84 (11), 2477–2482. 10.1111/bcp.13710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lv Y., Liu R., Xie S., Zheng X., Mao J., Cai Y., et al. (2017). Calcein-acetoxymethy ester enhances the antitumor effects of doxorubicin in nonsmall cell lung cancer by regulating the TopBP1/p53RR pathway. Anticancer Drugs 28 (8), 861–868. 10.1097/CAD.0000000000000527 [DOI] [PubMed] [Google Scholar]
  28. MacCallum C. A., Russo E. B. (2018). Practical considerations in medical cannabis administration and dosing. Eur. J. Intern Med. 49, 12–19. 10.1016/j.ejim.2018.01.004 [DOI] [PubMed] [Google Scholar]
  29. Mailander V., Landfester K. (2009). Interaction of nanoparticles with cells. Biomacromolecules 10 (9), 2379–2400. 10.1021/bm900266r [DOI] [PubMed] [Google Scholar]
  30. Martin-Cordero C., Leon-Gonzalez A. J., Calderon-Montano J. M., Burgos-Moron E., Lopez-Lazaro M. (2012). Pro-oxidant natural products as anticancer agents. Curr. Drug Targets 13 (8), 1006–1028. 10.2174/138945012802009044 [DOI] [PubMed] [Google Scholar]
  31. Mirza A. Z., Shamshad H. (2011). Preparation and characterization of doxorubicin functionalized gold nanoparticles. Eur. J. Med. Chem. 46 (5), 1857–1860. 10.1016/j.ejmech.2011.02.048 [DOI] [PubMed] [Google Scholar]
  32. Mishra P., Ahmad A., Al-Keridis L. A., Alshammari N., Alabdallah N. M., Muzammil K., et al. (2022). Doxorubicin-conjugated zinc oxide nanoparticles, biogenically synthesised using a fungus Aspergillus niger, exhibit high therapeutic efficacy against lung cancer cells. Molecules 27 (8), 2590. 10.3390/molecules27082590 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Mogheri F., Jokar E., Afshin R., Akbari A. A., Dadashpour M., Firouzi-amandi A., et al. (2021). Co-delivery of metformin and silibinin in dual-drug loaded nanoparticles synergistically improves chemotherapy in human non-small cell lung cancer A549 cells. J. Drug Deliv. Sci. Technol. 66, 102752. 10.1016/j.jddst.2021.102752 [DOI] [Google Scholar]
  34. Mukherjee S., Sau S., Madhuri D., Bollu V. S., Madhusudana K., Sreedhar B., et al. (2016). Green synthesis and characterization of monodispersed gold nanoparticles: toxicity study, delivery of doxorubicin and its bio-distribution in mouse model. J. Biomed. Nanotechnol. 12 (1), 165–181. 10.1166/jbn.2016.2141 [DOI] [PubMed] [Google Scholar]
  35. Park S. Y., Park K., Oh J. W., Park G. (2023). Gold nanoparticle encoded with marigold (Tagetes erecta L.) suppressed hyperglycemia-induced senescence in retinal pigment epithelium via suppression of lipid peroxidation. Arabian J. Chem. 16 (10), 105120. 10.1016/j.arabjc.2023.105120 [DOI] [Google Scholar]
  36. Rathos M. J., Khanwalkar H., Joshi K., Manohar S. M., Joshi K. S. (2013). Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer 13, 29. 10.1186/1471-2407-13-29 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ruenraroengsak P., Kiryushko D., Theodorou I. G., Klosowski M. M., Taylor E. R., Niriella T., et al. (2019). Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells. Nanoscale 11 (27), 12858–12870. 10.1039/c9nr01277j [DOI] [PubMed] [Google Scholar]
  38. Safwat M. A., Soliman G. M., Sayed D., Attia M. A. (2016). Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells. Int. J. Pharm. 513 (1-2), 648–658. 10.1016/j.ijpharm.2016.09.076 [DOI] [PubMed] [Google Scholar]
  39. Santiago T., DeVaux R. S., Kurzatkowska K., Espinal R., Herschkowitz J. I., Hepel M. (2017). Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine. Int. J. Nanomedicine 12, 7763–7776. 10.2147/IJN.S149306 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Sharma H., Kumar K., Choudhary C., Mishra P. K., Vaidya B. (2016). Development and characterization of metal oxide nanoparticles for the delivery of anticancer drug. Artif. Cells Nanomed Biotechnol. 44 (2), 672–679. 10.3109/21691401.2014.978980 [DOI] [PubMed] [Google Scholar]
  41. Singh D., Singh S., Sahu J., Srivastava S., Singh M. R. (2016). Ceramic nanoparticles: recompense, cellular uptake and toxicity concerns. Artif. Cells Nanomed Biotechnol. 44 (1), 401–409. 10.3109/21691401.2014.955106 [DOI] [PubMed] [Google Scholar]
  42. Singh P., Pandit S., Garnaes J., Tunjic S., Mokkapati V. R., Sultan A., et al. (2018a). Green synthesis of gold and silver nanoparticles from Cannabis sativa (industrial hemp) and their capacity for biofilm inhibition. Int. J. Nanomedicine 13, 3571–3591. 10.2147/IJN.S157958 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Singh P., Pandit S., Mokkapati V., Garg A., Ravikumar V., Mijakovic I. (2018b). Gold nanoparticles in diagnostics and therapeutics for human cancer. Int. J. Mol. Sci. 19 (7), 1979. 10.3390/ijms19071979 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209–249. 10.3322/caac.21660 [DOI] [PubMed] [Google Scholar]
  45. Thornberry N. A., Rano T. A., Peterson E. P., Rasper D. M., Timkey T., Garcia-Calvo M., et al. (1997). A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J. Biol. Chem. 272 (29), 17907–17911. 10.1074/jbc.272.29.17907 [DOI] [PubMed] [Google Scholar]
  46. Timkovich R. (1977). Detection of the stable addition of carbodiimide to proteins. Anal. Biochem. 79, 135–143. 10.1016/0003-2697(77)90387-6 [DOI] [PubMed] [Google Scholar]
  47. Tomuleasa C., Soritau O., Orza A., Dudea M., Petrushev B., Mosteanu O., et al. (2012). Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. J. Gastrointestin Liver Dis. 21 (2), 187–196. [PubMed] [Google Scholar]
  48. Trejo-Teniente I., Jaramillo-Loranca B. E., Vargas-Hernández G., Villanueva-Ibáñez M., Tovar-Jiménez X., Olvera-Venegas P. N., et al. (2024). Synthesis and toxicity assessment of Coffea arabica extract-derived gold nanoparticles loaded with doxorubicin in lung cancer cell cultures. Front. Bioeng. Biotechnol. 12, 1378601. 10.3389/fbioe.2024.1378601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Wang F., Wang Y. C., Dou S., Xiong M. H., Sun T. M., Wang J. (2011). Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 5 (5), 3679–3692. 10.1021/nn200007z [DOI] [PubMed] [Google Scholar]
  50. Zhang P., Li J., Ghazwani M., Zhao W., Huang Y., Zhang X., et al. (2015). Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy. Biomaterials 67, 104–114. 10.1016/j.biomaterials.2015.07.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Zhang X., Wang Q., Qin L., Fu H., Fang Y., Han B., et al. (2016). EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer. Drug Deliv. 23 (8), 2936–2945. 10.3109/10717544.2015.1126769 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Image1.TIF (6.5MB, TIF)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

Leave a Reply